{
    "title": "Nestle invests $200 mln more in Aimmune after peanut allergy drug approval",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7969839/Nestle-invests-200-mln-Aimmune-peanut-allergy-drug-approval.html",
    "date": "2020-02-05",
    "keywords": [
        "therapy",
        "investment",
        "aimmune",
        "health",
        "stock",
        "palforzia",
        "joseph",
        "science",
        "analyst",
        "raymond",
        "unit",
        "squeeze",
        "arm",
        "sa",
        "drugmaker",
        "approval",
        "peanut",
        "allergy",
        "blockbuster",
        "funding",
        "companys",
        "stake",
        "power",
        "morning",
        "trading",
        "tuesday",
        "friday",
        "weakness",
        "investor",
        "financing",
        "sandler",
        "christopher",
        "note",
        "prospect",
        "take",
        "anyone",
        "matter",
        "nestle",
        "wellness",
        "company",
        "role",
        "food",
        "part",
        "offering",
        "launch",
        "skorney",
        "decide",
        "performance",
        "couple",
        "interest",
        "measure",
        "money",
        "stood",
        "float",
        "jan",
        "license",
        "asthma",
        "inc",
        "payment",
        "cash",
        "equity",
        "reporting",
        "sibi",
        "bengaluru",
        "editing",
        "koyyur",
        "maju",
        "samuel",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}